Xilio Therapeutics, Inc.
Ticker: 1840233
values in millions
Revenue & Profit Trend
in millionsRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q1 FY2026 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 | Q2 FY2024 |
|---|---|---|---|---|---|---|
| INCOME | ||||||
| Revenue | 12.65-33.7% | 19.07+136.0% | 8.08+175.8% | 2.93+29.6% | 2.26-4.2% | 2.36 |
| Total Income | 12.65-33.7% | 19.07+136.0% | 8.08+175.8% | 2.93+29.6% | 2.26-4.2% | 2.36 |
| EXPENSES | ||||||
| Expenditure | 26.76+27.4% | 21.00-6.5% | 22.45+33.8% | 16.78-1.5% | 17.03-0.2% | 17.06 |
| PROFIT | ||||||
| Net Profit | -9.53+41.5% | -16.29-2.8% | -15.84-19.4% | -13.27+5.3% | -14.02-0.6% | -13.93 |
| KEY METRICS | ||||||
| OPM % | -100.00%-89.88pp | -10.12%+89.88pp | -100.00% | -100.00% | -100.00% | -100.00% |
| NPM % | -75.34%+10.08pp | -85.42%+14.57pp | -100.00% | -100.00% | -100.00% | -100.00% |
| EPS | -0.58-427.3% | -0.11+31.3% | -0.16+11.1% | -0.18+18.2% | -0.22+8.3% | -0.24 |
Corporate Events
Board MeetingXLO
202629Jun
Board Meeting
Appointment of Ben Harshbarger as Chief Legal Officer. Xili…
SEC Filing ↗ Board MeetingXLO
202610Jun
Board Meeting
2026 Annual Meeting of Stockholders held to elect Class II d…
SEC Filing ↗ Board MeetingXLO
202615Apr
Board Meeting
Dr. Blanchard elected as Class III Director, Chair of Compen…
SEC Filing ↗